BridgeBio’s heart disease drug Attruby sails past prescription estimates
BridgeBio revealed Thursday that prescriptions for its recently approved rare heart disease drug Attruby substantially beat analyst projections — an update that is likely to further boost confidence in the company's commercialization efforts. According to its ...
BridgeBio revealed Thursday that prescriptions for its recently approved rare heart disease drug Attruby substantially beat analyst projections — an update that is likely to further boost confidence in the company's commercialization efforts.
According to its ...
